- Home
- DNTH vs IGR Comparison
DNTH vs IGR Comparison
Compare DNTH & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- IGR
- Stock Information
- Founded
- DNTH 2015
- IGR 2004
- Country
- DNTH United States
- IGR United States
- Employees
- DNTH N/A
- IGR N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- IGR Finance Companies
- Sector
- DNTH Health Care
- IGR Finance
- Exchange
- DNTH Nasdaq
- IGR Nasdaq
- Market Cap
- DNTH 823.1M
- IGR 900.3M
- IPO Year
- DNTH N/A
- IGR N/A
- Fundamental
- Price
- DNTH $22.34
- IGR $5.64
- Analyst Decision
- DNTH Strong Buy
- IGR
- Analyst Count
- DNTH 8
- IGR 0
- Target Price
- DNTH $46.43
- IGR N/A
- AVG Volume (30 Days)
- DNTH 310.9K
- IGR 747.7K
- Earning Date
- DNTH 11-07-2024
- IGR 01-01-0001
- Dividend Yield
- DNTH N/A
- IGR 13.93%
- EPS Growth
- DNTH N/A
- IGR N/A
- EPS
- DNTH N/A
- IGR N/A
- Revenue
- DNTH $5,366,000.00
- IGR N/A
- Revenue This Year
- DNTH $44.94
- IGR N/A
- Revenue Next Year
- DNTH N/A
- IGR N/A
- P/E Ratio
- DNTH N/A
- IGR N/A
- Revenue Growth
- DNTH 51.41
- IGR N/A
- 52 Week Low
- DNTH $6.58
- IGR $3.88
- 52 Week High
- DNTH $33.77
- IGR $5.70
- Technical
- Relative Strength Index (RSI)
- DNTH 35.51
- IGR 43.19
- Support Level
- DNTH $19.85
- IGR $5.51
- Resistance Level
- DNTH $28.56
- IGR $5.60
- Average True Range (ATR)
- DNTH 2.05
- IGR 0.11
- MACD
- DNTH -0.73
- IGR 0.01
- Stochastic Oscillator
- DNTH 20.05
- IGR 48.57
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is the United States based diversified, closed-end management investment company. Its objective is high current income and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities located mainly in the developed markets of North America, Europe, Australia, and Asia. Its portfolio of investments consists of different sectors such as diversified, retail, industrial, residential, hotels, healthcare, and other sectors.